Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report
Lists
Only you see this
Abstract
This case indicates that alectinib is feasible and has a good safety profile as a neoadjuvant therapy for ALK-positive NSCLC. But further research is needed to determine how long the treatment should last for patients to get the most benefit. There is also the problem of pulmonary fibrosis in the process of alectinib neoadjuvant therapy, which needs to be solved urgently.
BibTeX
@inproceedings{wang2023left,
author = {Zirong Wang and Yu Shi and Pengfei Zhang and Yuan Chen},
title = {{Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report}},
booktitle = {Chinese},
year = {2023},
doi = {10.21037/cco-23-111},
}Loading related content...